Value-Based Arrangements in Medicaid Pharmacy Programs
This data is presented as an interactive tool that allows users to: filter by timeframe/year, select specific data columns (distributions), filter by state or geography, and view the data as a table, map, or trend chart.
As of July 1, 2019
| Location | Any Value Based Arrangements in Place with Manufacturer(s) | Plans to Implement a New Value Based Arrangement in 2020 |
|---|---|---|
| United States | Yes: 2, No: 48, NR: 1 | |
| Alabama | No | |
| Alaska | No | |
| Arizona | No | Planning to submit a SPA to CMS for VBP |
| Arkansas | No | Working preliminarily on a VBA for hepatitis C |
| California | No | |
| Colorado | No | |
| Connecticut | No | Looking into standard contracts that are available, possibly multi-state pooling of value-based contracts |
| Delaware | No | |
| District of Columbia | No | Exploring options for value-based contracting in FY 2020 |
| Florida | No | |
| Georgia | No | In preliminary discussion and planning to submit a SPA |
| Hawaii | No | |
| Idaho | No | |
| Illinois | No | |
| Indiana | No | Planning to begin requiring providers to abide by manufacturer outcomes agreements |
| Iowa | No | |
| Kansas | No | |
| Kentucky | No | Exploring the possibility of engaging in an VBA arrangement |
| Louisiana | No | Completing a SPA for a VBA |
| Maine | No | |
| Maryland | No | |
| Massachusetts | No | CMS approved MassHealth's SPA to authorize VBAs on July 31, 2019 |
| Michigan | No | Working to implement new VBA arrangements with emerging gene and cell therapies |
| Minnesota | No | |
| Mississippi | No | |
| Missouri | No | |
| Montana | No | |
| Nebraska | No | |
| Nevada | No | |
| New Hampshire | No | |
| New Jersey | No | Agency proposal pending possible legislative adoption and Governor approval |
| New Mexico | No | |
| New York | No | |
| North Carolina | No | |
| North Dakota | No | |
| Ohio | No | |
| Oklahoma | Yes | |
| Oregon | No | |
| Pennsylvania | No | |
| Rhode Island | No | |
| South Carolina | No | Currently reviewing possible models to engage with VBA |
| South Dakota | No | |
| Tennessee | No | |
| Texas | No | |
| Utah | NR | |
| Vermont | No | |
| Virginia | No | Exploring VBA options with high cost drugs, in particular spinal muscular atrophy (SMA) products, as well as any new agents with fast-track FDA approval |
| Washington | Yes | |
| West Virginia | No | |
| Wisconsin | No | |
| Wyoming | No |